vs

Side-by-side financial comparison of Arcturus Therapeutics Holdings Inc. (ARCT) and Camden Property Trust (CPT). Click either name above to swap in a different company.

Arcturus Therapeutics Holdings Inc. is the larger business by last-quarter revenue ($7.2M vs $5.3M, roughly 1.4× Camden Property Trust). On growth, Camden Property Trust posted the faster year-over-year revenue change (243.0% vs -68.4%). Over the past eight quarters, Camden Property Trust's revenue compounded faster (102.8% CAGR vs -56.5%).

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

Camden Property Trust is a publicly traded real estate investment trust that invests in apartments in the United States. As of December 31, 2023, the company owned interests in 176 apartment communities containing 59,800 apartment homes in the United States. It is the 14th largest owner of apartments in the United States.

ARCT vs CPT — Head-to-Head

Bigger by revenue
ARCT
ARCT
1.4× larger
ARCT
$7.2M
$5.3M
CPT
Growing faster (revenue YoY)
CPT
CPT
+311.4% gap
CPT
243.0%
-68.4%
ARCT
Faster 2-yr revenue CAGR
CPT
CPT
Annualised
CPT
102.8%
-56.5%
ARCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARCT
ARCT
CPT
CPT
Revenue
$7.2M
$5.3M
Net Profit
$156.0M
Gross Margin
Operating Margin
Net Margin
2954.1%
Revenue YoY
-68.4%
243.0%
Net Profit YoY
3.1%
283.5%
EPS (diluted)
$1.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARCT
ARCT
CPT
CPT
Q4 25
$7.2M
$5.3M
Q3 25
$17.2M
$2.6M
Q2 25
$28.3M
$2.6M
Q1 25
$29.4M
$2.5M
Q4 24
$22.8M
$1.5M
Q3 24
$41.7M
$1.7M
Q2 24
$49.9M
$2.6M
Q1 24
$38.0M
$1.3M
Net Profit
ARCT
ARCT
CPT
CPT
Q4 25
$156.0M
Q3 25
$-13.4M
$108.9M
Q2 25
$-9.2M
$80.7M
Q1 25
$-14.1M
$38.8M
Q4 24
$-30.0M
$40.7M
Q3 24
$-6.9M
$-4.2M
Q2 24
$-17.2M
$42.9M
Q1 24
$-26.8M
$83.9M
Operating Margin
ARCT
ARCT
CPT
CPT
Q4 25
Q3 25
-96.3%
Q2 25
-41.0%
Q1 25
-57.3%
Q4 24
-146.7%
Q3 24
-25.8%
Q2 24
-42.4%
Q1 24
-80.0%
Net Margin
ARCT
ARCT
CPT
CPT
Q4 25
2954.1%
Q3 25
-78.4%
4246.9%
Q2 25
-32.4%
3063.8%
Q1 25
-47.9%
1561.0%
Q4 24
-131.8%
2642.3%
Q3 24
-16.6%
-246.3%
Q2 24
-34.5%
1646.9%
Q1 24
-70.5%
6533.4%
EPS (diluted)
ARCT
ARCT
CPT
CPT
Q4 25
$1.44
Q3 25
$-0.49
$1.00
Q2 25
$-0.34
$0.74
Q1 25
$-0.52
$0.36
Q4 24
$-1.10
$0.37
Q3 24
$-0.26
$-0.04
Q2 24
$-0.64
$0.40
Q1 24
$-1.00
$0.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARCT
ARCT
CPT
CPT
Cash + ST InvestmentsLiquidity on hand
$230.9M
$25.2M
Total DebtLower is stronger
$3.9B
Stockholders' EquityBook value
$214.0M
$4.4B
Total Assets
$271.1M
$9.0B
Debt / EquityLower = less leverage
0.89×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARCT
ARCT
CPT
CPT
Q4 25
$230.9M
$25.2M
Q3 25
$180.4M
$25.9M
Q2 25
$196.5M
$33.1M
Q1 25
$216.9M
$26.2M
Q4 24
$237.0M
$21.0M
Q3 24
$237.2M
$31.2M
Q2 24
$260.3M
$93.9M
Q1 24
$288.4M
$92.7M
Total Debt
ARCT
ARCT
CPT
CPT
Q4 25
$3.9B
Q3 25
$3.7B
Q2 25
$3.8B
Q1 25
$3.7B
Q4 24
$3.5B
Q3 24
$3.5B
Q2 24
$3.6B
Q1 24
$3.6B
Stockholders' Equity
ARCT
ARCT
CPT
CPT
Q4 25
$214.0M
$4.4B
Q3 25
$224.6M
$4.5B
Q2 25
$231.1M
$4.6B
Q1 25
$233.8M
$4.6B
Q4 24
$241.0M
$4.7B
Q3 24
$261.9M
$4.7B
Q2 24
$258.6M
$4.9B
Q1 24
$264.0M
$4.9B
Total Assets
ARCT
ARCT
CPT
CPT
Q4 25
$271.1M
$9.0B
Q3 25
$282.3M
$9.1B
Q2 25
$309.3M
$9.1B
Q1 25
$331.8M
$9.0B
Q4 24
$344.1M
$8.9B
Q3 24
$370.7M
$8.9B
Q2 24
$388.6M
$9.1B
Q1 24
$418.8M
$9.1B
Debt / Equity
ARCT
ARCT
CPT
CPT
Q4 25
0.89×
Q3 25
0.82×
Q2 25
0.83×
Q1 25
0.81×
Q4 24
0.75×
Q3 24
0.73×
Q2 24
0.73×
Q1 24
0.72×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARCT
ARCT
CPT
CPT
Operating Cash FlowLast quarter
$-74.3M
$826.6M
Free Cash FlowOCF − Capex
$-74.5M
FCF MarginFCF / Revenue
-1035.2%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
5.30×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARCT
ARCT
CPT
CPT
Q4 25
$-74.3M
$826.6M
Q3 25
$-17.2M
$250.9M
Q2 25
$-5.8M
$230.7M
Q1 25
$-35.1M
$148.2M
Q4 24
$-284.0K
$774.9M
Q3 24
$-23.8M
$261.6M
Q2 24
$-30.1M
$225.1M
Q1 24
$-5.6M
$135.9M
Free Cash Flow
ARCT
ARCT
CPT
CPT
Q4 25
$-74.5M
Q3 25
$-17.3M
Q2 25
Q1 25
$-35.3M
Q4 24
Q3 24
$-23.8M
Q2 24
$-30.5M
Q1 24
$-5.8M
FCF Margin
ARCT
ARCT
CPT
CPT
Q4 25
-1035.2%
Q3 25
-101.1%
Q2 25
Q1 25
-120.1%
Q4 24
Q3 24
-57.2%
Q2 24
-61.1%
Q1 24
-15.3%
Capex Intensity
ARCT
ARCT
CPT
CPT
Q4 25
3.2%
Q3 25
1.1%
Q2 25
0.0%
Q1 25
0.5%
Q4 24
0.0%
Q3 24
0.2%
Q2 24
0.7%
Q1 24
0.6%
Cash Conversion
ARCT
ARCT
CPT
CPT
Q4 25
5.30×
Q3 25
2.30×
Q2 25
2.86×
Q1 25
3.82×
Q4 24
19.04×
Q3 24
Q2 24
5.24×
Q1 24
1.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons